Faricimab & Asciminib Are First Products To Be Approved By All Access Consortium Regulators
Executive Summary
A therapy for wet age-related macular degeneration and a new drug for leukemia have become the first two products to be approved by all countries involved in the international Access Consortium.
You may also be interested in...
The Evolution Of Drug Regulation In Post-Brexit Britain
Regulatory reliance is playing an increasingly important role in gaining marketing authorization in the UK following Brexit. Meanwhile, the country’s unique Innovative Licensing and Access Pathway is attracting growing levels of interest, not just from companies but from regulators and health technology appraisal bodies across the world.
High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share
The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.
Why Novartis Rejected Access Consortium In Favor Of Direct UK Radioligand Filing
A direct marketing authorization application to the UK medicines regulator offered a quicker route to approval for Novartis’ prostate cancer treatment Pluvicto than following the international Access Consortium process, because of the novel nature of the therapy, according to the company.